Different prognosis of patients with esophageal carcinoma with M1a and regional node involvement

Tae Ryong Chung; Jie Hyun Kim; Ik Jae Lee; Yeona Cho; Jun Won Kim; Chang Geol Lee; Da Hyun Jung; Jae Jun Park; Young Hoon Youn; Hyojin Park

doi:10.1016/j.dld.2019.05.014

Different prognosis of patients with esophageal carcinoma with M1a and regional node involvement

Tae Ryong Chung, Jie Hyun Kim, Ik Jae Lee, Yeona Cho, Jun Won Kim, Chang Geol Lee, Da Hyun Jung, Jae Jun Park, Young Hoon Youn, Hyojin Park

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Background and purpose: Based on the 6th edition of the American Joint Commission on Cancer (AJCC) staging system for esophageal squamous cell carcinoma (ESCC), M1a node involvement was classified as regional node involvement in the revised 7th/8th edition. However, the clinical significance of M1a node involvement is unclear. Thus, we analyzed the prognostic value of M1a node involvement in patients with ESCC after definitive concurrent chemoradiotherapy (CCRT). Materials and methods: In total, 188 patients with ESCC had M0 disease according to the 7th/8th edition AJCC. We reclassified 31 (16.5%) of these patients as having M1a disease according to the 6th edition. After definitive CCRT, we compared baseline characteristics between the two groups and analyzed the rates of responders and recurrence. Finally, we compared prognoses according to overall survival (OS), disease-specific OS, and disease-free survival (DFS). Results: Among 31 patients reclassified to have M1a disease, 21 (67.7%) had supraclavicular lymph node metastasis and 10 (32.3%) had celiac lymph node metastasis. The number of responders was significantly lower for M1a disease based on univariate (p = 0.004) and multivariate (p = 0.011) analyses. Significantly lower survival rates were observed in individuals with M1a disease (median OS, 16.4 vs. 42.7 months; 5-year OS, 10.8% vs. 41.2%). Conclusions: M1a node involvement should be differentiated from regional node involvement.

Original language	English
Pages (from-to)	1610-1616
Number of pages	7
Journal	Digestive and Liver Disease
Volume	51
Issue number	11
DOIs	https://doi.org/10.1016/j.dld.2019.05.014
Publication status	Published - 2019 Nov

Bibliographical note

Funding Information:
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology ( 2015R1C1A2A01053924 ).

Publisher Copyright:
© 2019 Editrice Gastroenterologica Italiana S.r.l.

All Science Journal Classification (ASJC) codes

Hepatology
Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.dld.2019.05.014

Cite this

@article{adbfb6de24e54b19952952ccd2a84632,

title = "Different prognosis of patients with esophageal carcinoma with M1a and regional node involvement",

abstract = "Background and purpose: Based on the 6th edition of the American Joint Commission on Cancer (AJCC) staging system for esophageal squamous cell carcinoma (ESCC), M1a node involvement was classified as regional node involvement in the revised 7th/8th edition. However, the clinical significance of M1a node involvement is unclear. Thus, we analyzed the prognostic value of M1a node involvement in patients with ESCC after definitive concurrent chemoradiotherapy (CCRT). Materials and methods: In total, 188 patients with ESCC had M0 disease according to the 7th/8th edition AJCC. We reclassified 31 (16.5%) of these patients as having M1a disease according to the 6th edition. After definitive CCRT, we compared baseline characteristics between the two groups and analyzed the rates of responders and recurrence. Finally, we compared prognoses according to overall survival (OS), disease-specific OS, and disease-free survival (DFS). Results: Among 31 patients reclassified to have M1a disease, 21 (67.7%) had supraclavicular lymph node metastasis and 10 (32.3%) had celiac lymph node metastasis. The number of responders was significantly lower for M1a disease based on univariate (p = 0.004) and multivariate (p = 0.011) analyses. Significantly lower survival rates were observed in individuals with M1a disease (median OS, 16.4 vs. 42.7 months; 5-year OS, 10.8% vs. 41.2%). Conclusions: M1a node involvement should be differentiated from regional node involvement.",

author = "Chung, {Tae Ryong} and Kim, {Jie Hyun} and Lee, {Ik Jae} and Yeona Cho and Kim, {Jun Won} and Lee, {Chang Geol} and Jung, {Da Hyun} and Park, {Jae Jun} and Youn, {Young Hoon} and Hyojin Park",

note = "Funding Information: This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology ( 2015R1C1A2A01053924 ). Publisher Copyright: {\textcopyright} 2019 Editrice Gastroenterologica Italiana S.r.l.",

year = "2019",

month = nov,

doi = "10.1016/j.dld.2019.05.014",

language = "English",

volume = "51",

pages = "1610--1616",

journal = "Digestive and Liver Disease",

issn = "1590-8658",

publisher = "Elsevier",

number = "11",

}

TY - JOUR

T1 - Different prognosis of patients with esophageal carcinoma with M1a and regional node involvement

AU - Chung, Tae Ryong

AU - Kim, Jie Hyun

AU - Lee, Ik Jae

AU - Cho, Yeona

AU - Kim, Jun Won

AU - Lee, Chang Geol

AU - Jung, Da Hyun

AU - Park, Jae Jun

AU - Youn, Young Hoon

AU - Park, Hyojin

N1 - Funding Information: This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology ( 2015R1C1A2A01053924 ). Publisher Copyright: © 2019 Editrice Gastroenterologica Italiana S.r.l.

PY - 2019/11

Y1 - 2019/11

N2 - Background and purpose: Based on the 6th edition of the American Joint Commission on Cancer (AJCC) staging system for esophageal squamous cell carcinoma (ESCC), M1a node involvement was classified as regional node involvement in the revised 7th/8th edition. However, the clinical significance of M1a node involvement is unclear. Thus, we analyzed the prognostic value of M1a node involvement in patients with ESCC after definitive concurrent chemoradiotherapy (CCRT). Materials and methods: In total, 188 patients with ESCC had M0 disease according to the 7th/8th edition AJCC. We reclassified 31 (16.5%) of these patients as having M1a disease according to the 6th edition. After definitive CCRT, we compared baseline characteristics between the two groups and analyzed the rates of responders and recurrence. Finally, we compared prognoses according to overall survival (OS), disease-specific OS, and disease-free survival (DFS). Results: Among 31 patients reclassified to have M1a disease, 21 (67.7%) had supraclavicular lymph node metastasis and 10 (32.3%) had celiac lymph node metastasis. The number of responders was significantly lower for M1a disease based on univariate (p = 0.004) and multivariate (p = 0.011) analyses. Significantly lower survival rates were observed in individuals with M1a disease (median OS, 16.4 vs. 42.7 months; 5-year OS, 10.8% vs. 41.2%). Conclusions: M1a node involvement should be differentiated from regional node involvement.

AB - Background and purpose: Based on the 6th edition of the American Joint Commission on Cancer (AJCC) staging system for esophageal squamous cell carcinoma (ESCC), M1a node involvement was classified as regional node involvement in the revised 7th/8th edition. However, the clinical significance of M1a node involvement is unclear. Thus, we analyzed the prognostic value of M1a node involvement in patients with ESCC after definitive concurrent chemoradiotherapy (CCRT). Materials and methods: In total, 188 patients with ESCC had M0 disease according to the 7th/8th edition AJCC. We reclassified 31 (16.5%) of these patients as having M1a disease according to the 6th edition. After definitive CCRT, we compared baseline characteristics between the two groups and analyzed the rates of responders and recurrence. Finally, we compared prognoses according to overall survival (OS), disease-specific OS, and disease-free survival (DFS). Results: Among 31 patients reclassified to have M1a disease, 21 (67.7%) had supraclavicular lymph node metastasis and 10 (32.3%) had celiac lymph node metastasis. The number of responders was significantly lower for M1a disease based on univariate (p = 0.004) and multivariate (p = 0.011) analyses. Significantly lower survival rates were observed in individuals with M1a disease (median OS, 16.4 vs. 42.7 months; 5-year OS, 10.8% vs. 41.2%). Conclusions: M1a node involvement should be differentiated from regional node involvement.

UR - http://www.scopus.com/inward/record.url?scp=85066450586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066450586&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2019.05.014

DO - 10.1016/j.dld.2019.05.014

M3 - Article

C2 - 31175014

AN - SCOPUS:85066450586

SN - 1590-8658

VL - 51

SP - 1610

EP - 1616

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

IS - 11

ER -

Different prognosis of patients with esophageal carcinoma with M1a and regional node involvement

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this